Heart Failure Program Development: A Practical Playbook

A regional hospital executive hears the same warning in every operating review. Heart failure readmissions are pressuring performance, inpatient throughput is deteriorating, and transfer volume to a competing system keeps rising. Cardiology leadership wants a dedicated service line, while finance wants proof that the program won't become another unfunded clinical initiative. The strategic decision is straightforward, but not simple: build, expand, or partner.

Table of Contents

• Why Hospitals Are Betting on Heart Failure Program Development - Choose the strategic path deliberately

• Building the Business Case That Survives the CFO - Build the model around controllable drivers - Use one page, not a promotional deck

• Designing the Clinical Pathway From Admission to Home - Set admission and consult triggers - Make discharge a scheduled event

• Staffing the Multidisciplinary Heart Failure Team - Ramp the team in phases

• Outpatient, Inpatient, and Remote Workflows That Connect - Add technology only when it changes care

• Quality Metrics and the 2024 Measure Update in Action - Translate measures into operating ownership

• Recruitment, Partnerships, and Your 90-Day Launch Plan

Why Hospitals Are Betting on Heart Failure Program Development

Heart failure program development has moved beyond the traditional outpatient clinic. Hospitals now need a coordinated operating model that connects emergency care, inpatient cardiology, post-discharge management, advanced therapies, device care, and community follow-up. The clinical case is strong. The operational case determines whether the service line survives.

The American Heart Association launched Get With The Guidelines–Heart Failure in 2005 as a national quality-improvement registry focused on inpatient heart failure care. Over its 20-year review, the initiative expanded to nearly 3 million patient records and was estimated to cover roughly one quarter of all heart failure hospitalizations (American Heart Association review). That growth shows what happens when a hospital treats heart failure as a system capability rather than a collection of individual physician decisions.

Choose the strategic path deliberately

A de novo build gives executives maximum control over referral criteria, staffing, EHR workflows, and financial governance. It also carries the greatest launch risk because physician recruitment, APP hiring, clinic space, infusion capacity, analytics, and referral development must move together.

Expanding an existing cardiology clinic is usually faster. The hospital can reuse scheduling infrastructure, nursing processes, diagnostic capacity, and established referral relationships. The risk is that the new program becomes a branded version of general cardiology, without protected staff time or protocols for rapid medication titration.

A partnership with an academic center or private advanced HF group reduces the immediate recruitment burden. It can provide specialty coverage, transplant and LVAD referral access, education, and clinical governance. The tradeoff is shared control, dependence on the partner's availability, and the need for a carefully written service-level agreement.

The right decision follows the hospital's actual operating profile:

• Referral base: A broad primary care and community cardiology network supports a scalable ambulatory model. A narrow referral base may favor partnership first.

• Emergency and inpatient volume: High ED utilization and frequent cardiology admissions justify embedded consult coverage and standardized inpatient triggers.

• Existing cardiology coverage: A hospital with general cardiology, electrophysiology, interventional cardiology, imaging, and device capabilities can build a layered service. A hospital without those foundations may need an external advanced HF partner.

• Workforce access: Recruitment feasibility matters as much as market demand. A program that can't staff medication titration and follow-up will create promises the hospital can't keep.

Strategic rule: The hospital shouldn't announce a comprehensive HF program until it has named the physician owner, APP operating model, referral partner, and post-discharge team.

The remaining decisions are operational. The business case must withstand finance review, the pathway must function from admission to home, and the workforce plan must match the available talent rather than an idealized org chart.

Building the Business Case That Survives the CFO

A CFO won't approve heart failure program development because the disease is clinically important. Approval requires a transparent model that separates avoidable utilization, captured revenue, operating expense, and clinical risk.

The strongest starting point is evidence that registry participation can improve use of guideline-recommended therapies, quality-measure adherence, care equity, and clinical outcomes. When Get With The Guidelines–Heart Failure launched in 2005, about one in three hospitalized patients with heart failure died within a year, underscoring why structured follow-up, discharge optimization, readmission tracking, and mortality review became central program functions (registry review).

Build the model around controllable drivers

The pro forma should distinguish between value the program can directly influence and value that depends on payer contracts or downstream behavior. Avoided readmissions, shorter stays, earlier outpatient follow-up, appropriate imaging, device evaluation, and clinic visit capture belong in separate lines. So do HRRP exposure, shared-savings arrangements, and contribution margin by HF-related DRG.

The cost stack should include more than physician salary:

• Clinical labor: HF cardiologist, APPs, nurse navigator, pharmacist, dietitian, and social work support.

• Infrastructure: Dedicated clinic capacity, infusion capability, device coordination, and referral management.

• Technology: EHR order sets, registry reporting, remote monitoring, analytics, and patient communication tools.

• Governance: Quality review, education, credentialing, data validation, and partner-management time.

A multidisciplinary disease-management model has been associated with a 24% reduction in all-cause hospitalization, a 42% reduction in heart-failure hospitalization, and a smaller, more variable mortality improvement in meta-analysis (disease-management evidence). Those findings support the clinical investment, but finance leaders should also see the limits. In the SPAN-CHF trial, a 90-day intervention reduced HF hospitalizations, while increased non-HF hospitalizations partly offset that effect. The study estimated a $375 per-patient reduction in hospitalization costs, but the net effect including program costs was an increase of $488 per patient. The intervention would have needed to be 24% cheaper to become cost saving (SPAN-CHF analysis).

Use one page, not a promotional deck

A defensible business case should fit on one page and show baseline utilization, the intervention, accountable owner, expense by category, expected operational effect, measurement cadence, and the break-even logic. No unsupported payback example should be presented as fact. Finance should receive a sensitivity analysis instead, with conservative, expected, and upside scenarios based on the hospital's own claims and EHR data.

Driver	Source / Assumption
Readmission exposure	Hospital baseline, payer mix, and applicable HRRP performance
Length of stay	Hospital case-mix and HF DRG data
Clinic contribution	Local reimbursement, capacity, and scheduled visit assumptions
Staffing expense	Approved compensation and FTE plan
Technology expense	Vendor proposal and implementation estimate
Downstream services	Historical imaging, device, infusion, and referral data
Shared savings	Executed payer or accountable-care arrangement
Break-even timing	Finance-approved sensitivity model

Hospitals should also align compensation and productivity assumptions with the broader physician strategy. A review of physician compensation models can help leadership separate base compensation, productivity, quality incentives, and service-line responsibilities before the pro forma reaches the CFO.

Designing the Clinical Pathway From Admission to Home

The pathway should make the right action easier for every clinician who touches the patient. It shouldn't depend on an individual cardiologist remembering to place a referral, a nurse finding an appointment, or a family member knowing which symptom requires a call.

Set admission and consult triggers

The ED and hospital medicine teams need explicit triggers for HF involvement. Those can include relevant BNP or NT-proBNP thresholds defined by local protocol, high inpatient cardiology consult demand, recurrent admissions, renal dysfunction complicating diuresis, reduced ejection fraction, suspected advanced disease, and social or medication-access barriers.

The inpatient assessment should answer four questions:

1. What is the patient's HF phenotype and ejection-fraction category?

2. What precipitated decompensation, such as ischemia, arrhythmia, infection, uncontrolled blood pressure, nonadherence, or medication toxicity?

3. Which components of guideline-directed medical therapy can begin or advance before discharge?

4. What outpatient resource will own the next decision?

A transthoracic echocardiogram, ischemia assessment when clinically indicated, medication reconciliation, renal and electrolyte review, device assessment, and evaluation for advanced HF features should feed one shared plan. The hospital shouldn't discharge a patient with a list of recommendations and no named clinician responsible for acting on them.

Make discharge a scheduled event

Discharge planning should include a completed checklist, medication reconciliation template, red-flag symptom list, confirmed appointment, and warm handoff to the outpatient HF clinic. The structured pathway should include a nurse call at 48 to 72 hours and a post-discharge visit within 7 days, with APP or HF cardiologist ownership of medication titration.

A telephone disease-management model has shown meaningful reductions in hospitalization, but implementation quality matters. Programs should monitor adherence, self-care, symptoms, weight trends when useful, renal function, blood pressure, and the speed of medication adjustment. Telemonitoring belongs inside that escalation process, not beside it as a separate technology project.

The most common hidden failure is education without confirmed teach-back. A patient may receive written instructions and still misunderstand the diuretic plan, sodium guidance, symptom thresholds, or whom to call. The nurse should ask the patient or caregiver to explain the medication schedule and escalation plan in their own words before the patient leaves.

Operational standard: Every discharge handoff should identify the next appointment, the medication decision pending, the person accountable for that decision, and the symptom that requires escalation.

Staffing the Multidisciplinary Heart Failure Team

The dream team isn't a launch plan. The United States has roughly 1,200 board-certified advanced HF cardiologists for more than 6.7 million patients with heart failure, so a new program must assume that advanced HF recruitment may take time and that the initial model will rely on disciplined delegation (workforce and outpatient decongestion review)).

The HF cardiologist medical director owns clinical governance, complex diagnosis, advanced therapy selection, quality review, and relationships with transplant and LVAD centers. The APPs manage protocol-driven follow-up, GDMT titration, volume assessment, lab review, and urgent access. The nurse navigator tracks referrals, coordinates discharge calls, closes appointment gaps, and escalates red flags.

The remaining roles need defined work, not ceremonial membership:

• Clinical pharmacist: Resolves medication-access barriers, reviews interactions, supports titration, and manages refill and adherence workflows.

• Dietitian: Delivers individualized nutrition counseling and reinforces practical sodium and fluid-management strategies.

• Social worker: Addresses transportation, caregiver capacity, insurance, housing, food access, and other barriers that can derail the plan.

• Device and electrophysiology liaison: Coordinates interrogation, arrhythmia evaluation, device alerts, and communication with electrophysiology and device clinics.

• Referral coordinator: Maintains community cardiology, primary care, ED, hospitalist, and advanced-therapy referral pathways.

Ramp the team in phases

A practical ramp begins with a physician, one APP, and a nurse navigator during months 0 to 6. That core can establish referral criteria, clinic templates, discharge workflows, and escalation rules.

During months 6 to 12, pharmacy and dietitian support should be added as patient volume and medication complexity increase. In year 2, the program should integrate the device team and formalize a heart transplant referral partner. These stages are planning benchmarks, not universal staffing mandates. Local volume, acuity, coverage, and partner access should determine the final design.

The critical governance decision is APP protocol authority. Hiring APPs without granting them approved titration protocols leaves every medication change with an overcommitted cardiologist. Clinic capacity then stalls, follow-up intervals lengthen, and the hospital blames demand for a problem created by role design.

Hospitals building this model can use advanced practice recruitment guidance for cardiology while defining supervision, privileging, prescribing, escalation, and documentation expectations. Recruitment isn't complete when a candidate signs. It is complete when the team can safely act without routing every routine decision back to one physician.

Outpatient, Inpatient, and Remote Workflows That Connect

A heart failure program stalls when its entry points operate as separate services. Outpatient clinicians manage longitudinal optimization, inpatient consultants stabilize patients and prepare transitions, and remote staff review signals only when they have authority to respond. Design the queue first, then assign the advanced HF cardiologist, APP, nurse, and device team to each decision.

The outpatient workflow starts before the visit. Staff review recent admissions, laboratory results, medication access, device data, symptoms, and the last titration decision. The APP or cardiologist makes a defined GDMT decision during the encounter. Between visits, the nurse navigator handles protocol-based symptom and adherence reviews. Protect capacity for the post-discharge appointment within 7 days. A scheduling target without reserved slots will fail as volume rises.

Inpatient consults need same-day triage criteria, daily rounding expectations for active decompensation, and a shared HF passport. The document should travel through the EHR and record the working phenotype, precipitant, medication changes, renal and electrolyte considerations, device status, follow-up appointment, and escalation contact. Device teams need a named handoff when device data changes the plan.

Setting	Team Owner	Key Trigger	Frequency	Primary Outcome	Common Failure Mode
Outpatient	HF APP and cardiologist	Referral, discharge, worsening symptoms	Scheduled and protocol-driven	GDMT optimization and stability	No protected rapid-access capacity
Inpatient	HF consult team	Admission or high-risk deterioration	Daily during active care	Safe stabilization and transition	Consult arrives too late
Remote	Nurse-led escalation team	Symptom, pressure, weight, or device signal	Protocol-defined review	Earlier intervention for selected patients	Alerts without action authority

Add technology only when it changes care

The SPAN-CHF III trial found that tablet-based telemonitoring did not further reduce HF or total hospitalizations when added to an established telephone disease-management backbone (telemonitoring trial evidence). Build the response pathway before buying the platform. Name the alert reviewer, response time, clinician authorized to adjust therapy, and threshold for an in-person assessment.

Weight-only monitoring creates noise when patients measure inconsistently or staff cannot act on the result. Implantable hemodynamic sensor monitoring, such as CardioMEMS-class technology, fits selected patients only when trained staff can interpret trends and follow a documented titration workflow. Remote blood pressure monitoring also needs explicit medication decisions, rather than passive data collection. Hospitals assessing that capability can review remote blood pressure monitoring workflows.

Technology test: If an alert does not produce a documented action, escalation, or appointment decision, it is an inbox burden, not a clinical workflow.

Quality Metrics and the 2024 Measure Update in Action

Quality measurement should protect the program from two opposite errors. The first is tracking only readmissions, which hides process failures. The second is collecting dozens of indicators without assigning owners or acting on the results.

Earlier HF quality programs focused on inpatient measures such as left ventricular ejection fraction assessment, ACE inhibitor use in patients with left ventricular systolic dysfunction, complete discharge instructions, and smoking-cessation counseling (earlier HF quality measures). The 2020 ACC/AHA measure set contains 18 measures, including 13 performance measures, 4 quality measures, 1 structural measure, and 2 rehabilitation performance measures (ACC/AHA measure set).

Translate measures into operating ownership

The dashboard should show achievement measures, patient experience, timeliness, utilization, and equity. The 2024 update added nine HF performance and quality measures. New performance measures include optimal blood pressure control in HFpEF, SGLT2 inhibitor use in HFrEF, and GDMT in hospitalized patients. Quality measures include SGLT2 inhibitor use in HFmrEF and HFpEF, GDMT optimization before intervention for chronic secondary severe mitral regurgitation, continuation of GDMT in HFimpEF, social determinants of health assessment, contraception and pregnancy counseling in cardiomyopathy, and monoclonal protein screening when interpreting bone scintigraphy for suspected transthyretin cardiac amyloidosis (2024 ACC/AHA update).

The measure set should drive a quarterly packet, not a retrospective report:

Measure	Source	Target	Owner	Cadence
GDMT optimization by EF category	EHR and registry	Locally approved benchmark	HF medical director and APP lead	Quarterly
Post-discharge appointment completion	Scheduling and EHR	Locally approved benchmark	Nurse navigator	Monthly and quarterly
30-day readmission	Claims and hospital data	Baseline-informed improvement goal	Quality and finance	Quarterly
Days to first HF clinic visit	Scheduling data	Locally approved access standard	Clinic manager	Monthly
Patient-reported health status	KCCQ workflow	Baseline and follow-up completion	Outcomes coordinator	Quarterly
Social determinants assessment	EHR documentation	Reliable completion across eligible patients	Case management	Quarterly

The C-suite presentation should show the trend, the operational cause, the accountable owner, and the next intervention. A budget defense is stronger when executives can see that a missed appointment reflects limited clinic capacity, a low SGLT2 inhibitor rate reflects prescribing or access barriers, and a weak KCCQ completion rate reflects workflow design rather than patient disinterest.

Recruitment, Partnerships, and Your 90-Day Launch Plan

Recruitment determines whether the program becomes a service line or remains a planning document. A national search firm can identify advanced HF cardiologists, an academic partnership can provide interim specialty coverage, and a locums-to-permanent bridge can protect launch continuity while permanent recruitment proceeds.

An APP-led model with a supervising cardiologist is often the smarter initial build for a community hospital. That model works only when the supervising physician defines escalation criteria and the APP receives protocol authority for follow-up, laboratory review, diuretic adjustment, and GDMT titration. A shared-service agreement with an academic center, a formal LVAD and transplant referral pact, and structured education support from device or pharmaceutical partners can compress the time between approval and first clinic.

The launch plan should be visible on one page:

• Days 1 to 30: Secure the executive sponsor, approve the FTE plan, identify the medical director, lock clinic space, and select the academic or advanced HF partner.

• Days 31 to 60: Post physician and APP roles, draft partnership MOUs, build EHR order sets, define referral triggers, and approve discharge and escalation protocols.

• Days 61 to 90: Hire or contract the initial team, shadow-train staff, test scheduling and handoffs, and run a soft-launch clinic with a defined pilot cohort.

The quiet failures are predictable. Leaders announce the program before staffing is secured. APPs arrive without protocols. The EHR build isn't tested with nurses. The referral partner has no response-time obligation. The remote platform launches without escalation coverage. A service line leader should block go-live until those issues have named owners and a documented workaround.

American Cardiology Group provides permanent physician recruitment, locum tenens coverage, advanced practice placement, and executive recruitment for hospitals and health systems building cardiology services, including heart failure and related subspecialty coverage. Hospitals planning heart failure program development can visit American Cardiology Group to discuss a recruitment and coverage strategy aligned with the program's clinical model, market, and launch timeline.